Nuocheng Jianhua: Hong Kong Stock Announcement: List of Directors and Their Roles and Functions
Hong Kong Stock Announcement: 2024 Interim Report
China International Finance Corporation\'s inspection opinions on the initial public offering of Nuochengjianhua Pharmaceutical Co., Ltd.\'s strategic placement and listing circulation of restricted shares
Hong Kong Stock Announcement: Monthly Statement of Changes in Securities
China International Finance Corporation\'s 2024 Semi-Annual Continuous Supervision and Follow-up Report on Nuochengjianhua Pharmaceutical Co., Ltd.
Hong Kong Stock Announcement: Next Day Disclosure Statement
Special report on the use of funds raised in the first half of 2024 by Innocare Pharmaceutical Co., Ltd.
Announcement from Innocare Pharmaceuticals Co., Ltd. on the 2024 mid-year performance briefing.
Legal Opinion of Fangda Law Firm regarding the 2024 Shareholders Annual Meeting of Innocare Pharma Limited, Shanghai.
Announcement of the Board of Directors of Innocare Pharmaceutical Co., Ltd.
Shanghai Rongzheng Enterprise Consulting Services (Group) Co., Ltd.'s independent financial advisor report on the first vesting period of Innocare Pharmaceutical Co., Ltd.'s 2023 STAR Market restricted stock incentive plan that meets the attribution conditions for the first time.
Announcement of Board Resolutions of Nuochengjianhua Pharmaceutical Co., Ltd.
Independent Financial Advisory Report of Shanghai Rongzheng Enterprise Consulting Service (Group) Co., Ltd. on Nuochengjianhua Pharmaceutical Co., Ltd.'s 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan Reservation and Grant
Announcement of Nuochengjianhua Pharmaceutical Co., Ltd. on the use of some temporarily idle funds raised for cash management and storage of raised funds by means of notification deposits, agreement deposits, etc.
Verification opinions of China International Finance Corporation on Nuochengjianhua Pharmaceutical Co., Ltd.'s use of some temporarily idle funds raised for cash management and storage of raised funds by means of notification deposits, agreement deposits, etc.
Nuochengjianhua Pharmaceutical Co., Ltd. 2023 Environmental, Social and Governance Report
Ernst & Young Huaming Certified Public Accountants (Special General Partnership) Special Notice on the 2023 Operating Income Deduction Situation of Nuochengjianhua Pharmaceutical Co., Ltd.
Ernst & Young Huaming Certified Public Accountants (Special General Partnership) Audit Report on the Storage and Actual Use of Funds Raised by Nuochengjianhua Pharmaceutical Co., Ltd. in 2023
Announcement of Nuochengjianhua Pharmaceutical Co., Ltd. on renewing the employment of an accounting firm
Special report on the storage and actual use of funds raised by Nuochengjianhua Pharmaceutical Co., Ltd. in 2023
No Data
No Data